Assessment of the therapeutic range of tiapride in patients with tardive dyskinesia

RAC ROOS,* EA VAN DER VELDE,+ OJS BURUMA,* FA DE WOLFF, Ph.D†

From the Department of Neurology,* and Toxicology Laboratory,+ University Hospital, and Department of Medical Statistics,+ State University, Leiden, the Netherlands

SUMMARY Ten patients with tardive dyskinesia were treated with tiapride at an increasing dosage to establish the dose-concentration relationship and the dose-effect relationship. The effect was scored with the Abnormal Involuntary Movement Scale (AIMS) and the Doppler-radar method. The intra individual dosage-serum concentration correlation coefficients varied from 0.86 to 0.99 and the slopes of the individual regression lines varied from 0.16 to 0.58. All patients showed a diminution of their involuntary movements during the treatment period. A negative correlation coefficient was found between the dosage of tiapride and the AIMS; range -0.22 till -0.93, mean: -0.65 ± 0.23 (SD). The Doppler-radar method results were inconclusive. No side-effects were observed.

Tiapride, a substituted benzamide, is used in clinical practice in several involuntary movement disorders with variable therapeutic effects. Beneficial effects, in some of the patients studied, are reported in tardive dyskinesia,1–6 Huntington's chorea,7 3 7 and levodopa induced dyskinesia.2–4 However, no discrimination could be made between patients responding with a decrease of involuntary movements, the so-called responders, and the non-responders. Studies in healthy young volunteers and in elderly patients8 showed that tiapride is rapidly absorbed after oral and intramuscular administration. The peak concentration is reached within two hours and the half life time of elimination is about 3.5 hours.9 10 Tiapride is mainly eliminated in unmetabolised form in the urine.

The first aim of this study was to establish the relationship between dosage and serum concentrations of tiapride in patients with tardive dyskinesia. The second aim was to find out whether a relationship exists between serum concentration and effect, namely a decrease of involuntary movements. In other words, to establish the therapeutic range for tiapride.

Patients and methods

Ten chronic schizophrenic patients, three males and seven females, with tardive dyskinesia were studied. Their mean age was 63.5 years (46–73 years). All patients stayed in a chronic care unit of a psychiatric hospital (Psychiatric Hospital Edegeest, Oegstgeest). Patients with diseases of the central nervous system, and patients with renal, hepatic or gastrointestinal diseases were excluded. All patients gave their informed consent and the study was approved by the Medical Ethics Committee of the University Hospital of Leiden. Previously prescribed medication was continued throughout the trial and had been unchanged for at least three months prior to the study. The prescribed medication included: promethazine, perphenazine, levomepromazine, flupenthixol, fluphenazine, haloperidol, pimozide, bromperidol, lorazepam, orphenadrine, amantadine, amitriptyline, carbamazepine and phenobarbital. All patients started with three daily dosages of 100 mg tiapride for one week at 08.00 hrs, 15.00 hrs, and 22.00 hr. On the seventh day a serum concentration-time curve in blood was obtained. The dosage was increased (fig 1) up to a maximum

![Scheme of protocol](http://jnnp.bmj.com/content/49/9/1055/F1.large.jpg)

**Fig 1** Scheme of protocol; E = evaluation.
of 1200 mg daily. Evaluations took place after one week, and subsequently every fortnight. Each evaluation lasted about two hours and consisted of the following examinations. Involuntary movements were rated with the Abnormal Involuntary Movement Scale (AIMS)\(^1\) by two examiners independently, the mean score was used. The amount of orofacial involuntary movements was also measured by means of a Doppler-radar device.\(^2\) The mean value of two one-minute scores was taken. A three point self-assessment scale was filled in by the patients. Blood samples were taken just before the morning dose of tiapride \((t_0)\), and after two hours \((t_2)\). The serum was stored at \(-20^\circ\text{C}\) until analysed with a SP-HPLC method. The assay method for the tiapride determination is the following: to 200 \(\mu\text{l}\) of either patients’ serum or standard sera spiked with 0–40 \(\mu\text{g/ml}\) tiapride are added respectively 50 \(\mu\text{l}\) NaoH 1.5 \(\text{mol/l}\), 200 \(\mu\text{l}\) internal standard (N-propionylprocainamide 10 \(\mu\text{g/ml}\) in dichloromethane) and 7 ml dichloromethane. After 10 minutes mixing and 5 minutes centrifuging the upper layer is discarded and the organic layer is evaporated until dryness at 45°C under nitrogen. The residue is dissolved in 50 \(\mu\text{l}\) eluent of which 20 \(\mu\text{l}\) is injected into an HPLC equipped with an UV detector operating at 230 nm. The column is a 100 × 3 mm Lichrosorb Si 60 5 \(\mu\text{m}\); the eluent is composed of acetonitrile 250, methanol 55, ammonium hydroxide (1 mol/l) 13. Flow rate is 0.8–1.0 \(\mu\text{l/min}\). Details of this method will be published elsewhere. Serum creatinine and gamma-GT were determined as parameters for renal and liver function, respectively.

**Results**

Three weeks after the start of the trial one patient became psychotic and had to be excluded. Tiapride was discontinued immediately without any effect on the psychosis. The patient did not respond to changes in his neuroleptic drugs for the first month. One other patient was withdrawn after seven weeks because of an epileptic fit. The serum levels of carbamazepine and phenobarbital were within the therapeutic range.

---

**Fig 2** Dosage of tiapride versus mean serum concentrations (±SEM) for nine patients with tardive dyskinesia. The mean slope of regression is also given (0.30).

**Fig 3** Regression lines of dosage of tiapride and serum concentration in nine patients with tardive dyskinesia.
Assessment of the therapeutic range of tiapride in patients with tardive dyskinesia

The beneficial effect of tiapride in tardive dyskinesia has been reported in one double-blind cross-over clinical trial of four weeks and with a doses up to 300 mg tiapride daily and in several open trials. Because the optimum dose and long term effects of tiapride are still largely unknown this study of longer duration and with increasing dosage was undertaken. Both the positive correlation between dosage and blood levels of tiapride and the negative correlation between tiapride dosage and AIMS-score showed that an increase of dosage above 300 mg daily results in a further reduction of involuntary movements. The maximum response, namely a total absence of involuntary movements, was not reached. These results leave the question unanswered whether a dosage exceeding 1200 mg tiapride daily, will result in still further diminution of involuntary movements.

In summary, we found a linear relationship between dosage of tiapride and serum concentration in the individual patient. Because of the large inter-individual differences in dose-concentration relationships it might be useful to determine the tiapride serum concentration in the initial period of treatment in each patient. Tiapride diminished the involuntary movements more effectively in higher dosages, and during longer periods of treatment. We could not establish an upper limit for the therapeutic concentration of tiapride. Dosages up to 1200 mg daily were tolerated without any side effects. Whether tiapride diminishes involuntary movements without itself inducing them after longer periods of treatment cannot be concluded from this study. However, no reports of the induction of involuntary movements by tiapride in man have yet been published.

We thank IG Goekoop MD for the Psychiatric Hospital Endegeest, Oegstgeest for his help in selecting the patients. J van de Nes MD is thanked for his assistance. Mr EJM de Haas determined the serum concentrations of tiapride. DelaGrange supplied the tiapride. Miss A Koeztsier and Mrs KN Wagensveld-Hansen typed the manuscript.

References

3 Lipcsey A, Nagy E. Expérience clinique du tiapride en


